PDAC– tag –
-
What the Epigenetic Memory of Colitis Reveals: AP-1 Imprints Persisting 100+ Days That Drive Cancer | Cancer Origin Vol.3 (Final)
Nagaraja et al. Nature 2026/4/16: chronic colitis leaves AP-1-dependent epigenetic memory in colonic stem cell chromatin that persists for 100+ days. SHARE-TRACE proves clonal inheritance through stem cell divisions. Memory + APC mutation cooperatively accelerates tumor formation; AP-1 inhibition eliminates acceleration. New IBD-cancer prevention paradigm. Final volume. -
What Cerebellar Organoids Reveal About Medulloblastoma’s Origin: 3 Axes Toward Precision Medicine | Cancer Origin Vol.2
Cell April 2026 paper used human iPSC-derived cerebellar organoids + CRISPR to reproduce all four medulloblastoma subtypes (WNT, SHH, Group 3, Group 4) in real time. Cell of origin for each subtype directly confirmed. Vismodegib and BET inhibitor responses validated in subtype-specific manner. Personalized-therapy organoid proof of concept. Vol. 2. -
The Window Where Cancer Is Born — Progenitor Niche and the Benign-to-Malignant Transition | Frontiers of Cancer Origin Research, Vol. 1
Reyes et al. Cell May 2026: PDAC's benign-to-malignant transition happens in a rare progenitor-like cell population that assembles a self-reinforcing niche. Tumor-driving and tumor-suppressing programs (p53, CDKN2A, SMAD4) co-activate in these cells. KRAS inhibition or p53 activation collapses the niche and delays malignancy. Vol. 1. -
Latest Science News: G2-Biased Stress Granules Driven by cPLA2: A New Vulnerability Shaping Chemotherapy Response in PDAC
Across pancreatic ductal adenocarcinoma (PDAC) models, tumor cells show marked intercellular heterogeneity in stress granules (SGs). A single-cell, cell-cycle–aware view reveals that SGs are maximally enriched in G2, powered by a lipid m... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Comprehensive Summary and Future Outlook
Trilogy Subtitles＋Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance③
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance②
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...
1